



Montana Department of
ENVIRONMENTAL QUALITY

Brian Schweitzer, Governor

P. O. Box 200901

Helena, MT 59620-0901

(406) 444-2544

Website: www.deq.mt.gov

March 3, 2011

Mr. Michael Covarrubias
Corixa Corporation d/b/a GlaxoSmithKline Biologicals, NA
553 Old Corvallis Road
Hamilton, MT 59840

Dear Mr. Covarrubias:

Montana Air Quality Permit #4460-01 is deemed final as of March 3, 2011, by the Department of Environmental Quality (Department). This permit is for a pharmaceutical preparations facility. All conditions of the Department's Decision remain the same. Enclosed is a copy of your permit with the final date indicated.

For the Department,

Vickie Walsh
Air Permitting Program Supervisor
Air Resources Management Bureau
(406) 444-9741

Deanne Fischer, P.E.
Environmental Engineer
Air Resources Management Bureau
(406) 444-3403

VW:DF
Enclosure

DEPARTMENT OF ENVIRONMENTAL QUALITY
Permitting and Compliance Division
Air Resources Management Bureau
P.O. Box 200901, Helena, Montana 59620
(406) 444-3490

FINAL ENVIRONMENTAL ASSESSMENT (EA)

Issued To: Corixa Corporation d/b/a GlaxoSmithKline Biologicals, NA

Montana Air Quality Permit Number #: 4460-01

Preliminary Determination Issued: 01/26/2011

Department Decision Issued: 02/15/2011

Permit Final: 03/03/2011

1. *Legal Description of Site:* S ½ of Section 7, Township 6 North Range 20 West, Ravalli County, Montana
2. *Description of Project:* On October 19, 2010, the Department received a complete application for a modification to MAQP #4460-00 to include the following changes:
 - GSK would change the process for producing product in Building 12 from the High Density process to the Low Density process.
 - GSK determined that the cooling water temperature supplied to the condensation emission control systems in Building 5 is slightly higher than presented in the original permit application. Also the chilled water temperature supplied to the condensation emission control systems in Building 12 is higher than presented in the original permit application. These changes in water temperature increase the volatile organic compounds (VOC) and hazardous air pollutants (HAP) emissions from both buildings slightly, and should be noted in the permit.
 - GSK proposed to change the method of monitoring the operation of the condensation emission control systems in both Building 5 and Building 12. Instead of measuring the exhaust gas temperature from each condenser, as outlined in Section II.A. of the permit, the inlet cooling water and inlet chilled water temperatures would be measured.
 - Lastly, GSK noted that there was a misrepresentation of the number of laboratory hoods included as point sources in the emissions inventory in the previous permit. This modification would correct the emissions inventory calculations.
3. *Objectives of Project:* The objective of this permitting action is to identify the change in the type of manufacturing process in Building 12 (from High Density to Low Density), modify the inlet water temperature and means of monitoring the cooling temperature at the condensers in Buildings 5 and 12, and to correct the number of vent hoods included in the emissions inventory.
4. *Alternatives Considered:* In addition to the proposed action, the Department also considered the “no-action” alternative. The “no-action” alternative would deny issuance of the air quality preconstruction permit to the proposed facility. However, the Department does not consider the “no-action” alternative to be appropriate because GSK demonstrated compliance with all applicable rules and regulations as required for permit issuance. Therefore, the “no-action” alternative was eliminated from further consideration.

5. *A Listing of Mitigation, Stipulations, and Other Controls:* A list of enforceable conditions, including a BACT analysis, would be included in MAQP #4460-01.
6. *Regulatory Effects on Private Property:* The Department considered alternatives to the conditions imposed in this permit as part of the permit development. The Department determined that the permit conditions are reasonably necessary to ensure compliance with applicable requirements and demonstrate compliance with those requirements and do not unduly restrict private property rights.
7. *The following table summarizes the potential physical and biological effects of the proposed project on the human environment. The “no-action” alternative was discussed previously.*

		Major	Moderate	Minor	None	Unknown	Comments Included
A	Terrestrial and Aquatic Life and Habitats			X			Yes
B	Water Quality, Quantity, and Distribution			X			Yes
C	Geology and Soil Quality, Stability and Moisture			X			Yes
D	Vegetation Cover, Quantity, and Quality			X			Yes
E	Aesthetics				X		Yes
F	Air Quality			X			Yes
G	Unique Endangered, Fragile, or Limited Environmental Resources			X			Yes
H	Demands on Environmental Resource of Water, Air and Energy			X			Yes
I	Historical and Archaeological Sites			X			Yes
J	Cumulative and Secondary Impacts			X			Yes

SUMMARY OF COMMENTS ON POTENTIAL PHYSICAL AND BIOLOGICAL EFFECTS: The following comments have been prepared by the Department.

- A. Terrestrial and Aquatic Life and Habitats
- B. Water Quality, Quantity and Distribution
- C. Geology and Soil Quality, Stability and Moisture
- D. Vegetation Cover, Quantity, and Quality

Previous MEPA analysis for the permitted pharmaceutical preparations facility determined that GSK is an existing site with existing emitting units and would be considered a minor source of emissions. No additional land disturbance is included in this proposed action and only minor increases in pollutant emissions are expected. Therefore, only minor impacts, if any, would be expected to vegetation cover, quantity, and quality as a result of this permitting action.

E. Aesthetics

As this facility has existed in some form for more than a decade, this permitting action (permitting units that have already been installed) would have no effect on aesthetics.

F. Air Quality

The air quality impacts from this permitting action would be minor because MAQP #4460-01 would include conditions limiting emissions of regulated pollutants. The permitting action would require specific operation of the installed emitting units for the protection of air quality. In addition, the facility would be considered a minor source of air pollution by industrial standards and would be located in an area where good air dispersion would occur. Therefore, air quality impacts would be minor.

G. Unique Endangered, Fragile, or Limited Environmental Resources

The Department, in an effort to assess any potential impacts to any unique endangered, fragile, or limited environmental resources in the area of operation, contacted the Montana Natural Heritage Program (MNHP). Search results of databases indicated 6 species occurrence reports for 6 species of concern: the gray wolf, fisher, Canada lynx, marten, wolverine, and grizzly bear.

The GSK pharmaceutical preparations facility is an existing site with existing emitting units. The 35-acre industrial site has existed in some form for more than a decade. As these species of concern generally avoid areas of human activity, this permitting action would have a minor impact on their habitats and life.

H. Demands on Environmental Resource of Water, Air and Energy

The GSK pharmaceutical preparations facility is an existing site with existing emitting units. As previously mentioned, it is the intent of this action to appropriately permit the facility. GSK would be considered a minor source of air emissions. No additional water or energy resources would be expended as a result of this permitting action, therefore overall impact on the environmental resources of water, air, and energy would be minor.

I. Historical and Archaeological Sites

The Department contacted the Montana Historical Society for a cultural resource file search for the area of the proposed project location. According to their records there are no previously recorded sites in the area of the GSK facility. The location is a currently active manufacturing site and no new historical or archaeological sites are expected to be found within the GSK facility area.

J. Cumulative and Secondary Impacts

Potential physical and biological effects of any individual considerations above would be expected to be minor. Collectively, the potential cumulative and secondary impacts would be expected to be minor because the facility is an existing facility and the current permit action will result in relatively small increases in pollutant emissions.

8. The following table summarizes the potential economic and social effects of the proposed project on the human environment. The “no-action” alternative was discussed previously.

		Major	Moderate	Minor	None	Unknown	Comments Included
A	Social Structures and Mores			X			Yes
B	Cultural Uniqueness and Diversity			X			Yes
C	Local and State Tax Base and Tax Revenue			X			Yes
D	Agricultural or Industrial Production			X			Yes
E	Human Health			X			Yes
F	Access to and Quality of Recreational and Wilderness Activities			X			Yes
G	Quantity and Distribution of Employment				X		Yes
H	Distribution of Population				X		Yes
I	Demands for Government Services			X			Yes
J	Industrial and Commercial Activity			X			Yes
K	Locally Adopted Environmental Plans and Goals			X			Yes
L	Cumulative and Secondary Impacts			X			Yes

SUMMARY OF COMMENTS ON POTENTIAL ECONOMIC AND SOCIAL EFFECTS: The following comments have been prepared by the Department.

- A. Social Structures and Mores
- B. Cultural Uniqueness and Diversity
- C. Local and State Tax Base and Tax Revenue
- D. Agricultural or Industrial Production

The GSK pharmaceutical preparations facility is an existing site with existing emitting units. As previously mentioned, it is the intent of this action to appropriately permit the facility. GSK would be considered a minor source of emissions. The 35-acre industrial site has existed in some form for more than a decade; emitting units added in the last several years pushed the facility potential emissions over the permitting threshold. The facility would be small by industrial standards and would have a relatively small amount of pollutants emitted as a result of the operations. The proposed modifications include changes to existing equipment, and minor increases in pollutant emissions. Therefore, the facility would have minor impacts on social structures and mores, cultural uniqueness and diversity, local and state tax base and tax revenue, and agricultural or industrial production.

E. Human Health

The proposed project would result in minor impacts to human health because of the air emissions discharged from the facility. The project, permitted by MAQP #4460-01, would comply with all applicable air quality rules, regulations, and standards. These rules, regulations, and standards are designed to be protective of human health.

F. Access to and Quality of Recreational and Wilderness Activities

The Department is not aware of any direct access to recreational or wilderness activities which this project would affect. The facility currently exists, the permitting action addresses changes to the manufacturing operations within existing buildings, minor emissions increases, and brings the facility into compliance with air quality regulations. Any impacts to the access and quality of recreational and wilderness activities would be expected to be minor.

G. Quantity and Distribution of Employment

No new employees would be added as a result of this permitting action, therefore, the quantity and distribution of employment would remain unchanged.

H. Distribution of Population

The distribution of population around the GSK Hamilton facility is expected to remain unchanged. No new employees would be added as a result of this permitting action, therefore no workers would be moving into the area on the basis of this project.

I. Demands for Government Services

It would be expected that there would be demand for government services associated with compliance activities and acquiring the proper permits related to this project. However, overall demands for government services would be minor due to the size/classification of this facility.

J. Industrial and Commercial Activity

The current level of industrial and commercial activity would be maintained with the appropriate permitting of the GSK Hamilton facility. Therefore, there would be no impact on industrial and commercial activity for this action.

K. Locally Adopted Environmental Plans and Goals

The Department is not aware of any locally adopted environmental plans and goals affected by issuing MAQP #4460-01. The MAQP would contain limits for protecting air quality and keeping facility emissions in compliance with any applicable air quality standards.

L. Cumulative and Secondary Impacts

Potential economic and social effects of any individual considerations above would be expected to be minor. The Department has determined that collectively, the potential cumulative and secondary impacts would be expected to be minor because the facility is an existing facility and the current permit action will result in relatively small increases in pollutant emissions.

Recommendation: No Environmental Impact Statement (EIS) is required.

The current permitting action is for identifying the change in the type of manufacturing process in Building 12 (from High Density to Low Density), modifying the inlet water temperature and means of monitoring the cooling temperature at the condensers in Buildings 5 and 12, and correcting the number of vent hoods included as point sources in the emissions inventory. MAQP #4460-01 includes conditions and limitations to ensure the facility will operate in compliance with all applicable rules and regulations. In addition, there are no significant impacts associated with this proposal.

Other groups or agencies contacted or which may have overlapping jurisdiction: Montana Historical Society – State Historic Preservation Office, Natural Resource Information System – Montana Natural Heritage Program

Individuals or groups contributing to this EA: Department of Environmental Quality – Air Resources Management Bureau, Montana Historical Society – State Historic Preservation Office, Natural Resource Information System – Montana Natural Heritage Program

EA prepared by: Deanne Fischer

Date: December 29, 2010